5 Biotech Stocks with Huge Potential

2. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Holders: 59

Based in Tarrytown, New York, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biotechnology company that focus on developing therapies for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases.

On February 23, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that it the FDA has accepted for Priority Review the application for Dupixent® (dupilumab) in a sixth potential indication as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD). If approved, Dupixent would be the only biologic therapy for COPD. The Priority Review has been granted based on positive results from two Phase 3 trials.

Following the announcement, RBC Capital raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares to $1184 from $1096 and maintained an ‘Outperform’ rating on the shares.